These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 17319952)

  • 1. Evaluation of a recombinant human gelatin as a substitute for a hydrolyzed porcine gelatin in a refrigerator-stable Oka/Merck live varicella vaccine.
    Liska V; Bigert SA; Bennett PS; Olsen D; Chang R; Burke CJ
    J Immune Based Ther Vaccines; 2007 Feb; 5():4. PubMed ID: 17319952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restriction fragment differences between the genomes of the Oka varicella vaccine virus and American wild-type varicella-zoster virus.
    Adams SG; Dohner DE; Gelb LD
    J Med Virol; 1989 Sep; 29(1):38-45. PubMed ID: 2573686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the Whole-Genome Sequence of an Oka Varicella Vaccine from China with Other Oka Vaccine Strains Reveals Sites Putatively Critical for Vaccine Efficacy.
    Wu Q; Rivailler P; Xu S; Xu W
    J Virol; 2019 May; 93(9):. PubMed ID: 30728261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety profile of varicella vaccine: a 10-year review.
    Galea SA; Sweet A; Beninger P; Steinberg SP; Larussa PS; Gershon AA; Sharrar RG
    J Infect Dis; 2008 Mar; 197 Suppl 2():S165-9. PubMed ID: 18419392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial.
    Trannoy E; Berger R; Holländer G; Bailleux F; Heimendinger P; Vuillier D; Creusvaux H
    Vaccine; 2000 Feb; 18(16):1700-6. PubMed ID: 10689152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete DNA sequences of two oka strain varicella-zoster virus genomes.
    Tillieux SL; Halsey WS; Thomas ES; Voycik JJ; Sathe GM; Vassilev V
    J Virol; 2008 Nov; 82(22):11023-44. PubMed ID: 18787000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction of Oka varicella vaccine expressing human immunodeficiency virus env antigen.
    Shiraki K; Sato H; Yoshida Y; Yamamura JI; Tsurita M; Kurokawa M; Kageyama S
    J Med Virol; 2001 Jun; 64(2):89-95. PubMed ID: 11360239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind, randomized, controlled, multi-center safety and immunogenicity study of a refrigerator-stable formulation of VARIVAX®.
    Reisinger KS; Richardson E; Malacaman EA; Levin MJ; Gardner JL; Wang W; Stek JE; Kuter B
    Vaccine; 2019 Sep; 37(38):5788-5795. PubMed ID: 30146405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety profile of live varicella virus vaccine (Oka/Merck): five-year results of the European Varicella Zoster Virus Identification Program (EU VZVIP).
    Goulleret N; Mauvisseau E; Essevaz-Roulet M; Quinlivan M; Breuer J
    Vaccine; 2010 Aug; 28(36):5878-82. PubMed ID: 20600487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dose-response study of a live attenuated varicella-zoster virus (Oka strain) vaccine administered to adults 55 years of age and older.
    Berger R; Trannoy E; Holländer G; Bailleux F; Rudin C; Creusvaux H
    J Infect Dis; 1998 Nov; 178 Suppl 1():S99-103. PubMed ID: 9852985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of Oka/Merck varicella vaccine in children vaccinated at 12-14 months of age versus 15-23 months of age.
    Silber JL; Chan IS; Wang WW; Matthews H; Kuter BJ
    Pediatr Infect Dis J; 2007 Jul; 26(7):572-6. PubMed ID: 17596796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Characterization analysis of gM, gL genes of varicella zoster virus in six provinces of China].
    Mou JJ; Qi MY; Li CS; Zheng HY; Chen M; Zhou JH; He JL; Xu WW; Xu ST; Xu XG
    Zhonghua Yu Fang Yi Xue Za Zhi; 2018 Apr; 52(4):419-423. PubMed ID: 29614611
    [No Abstract]   [Full Text] [Related]  

  • 13. New method of differentiating wild-type varicella-zoster virus (VZV) strains from Oka varicella vaccine strain by VZV ORF 6-based PCR and restriction fragment length polymorphism analysis.
    Takayama M; Takayama N
    J Clin Virol; 2004 Feb; 29(2):113-9. PubMed ID: 14747030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The glycoprotein products of varicella-zoster virus gene 14 and their defective accumulation in a vaccine strain (Oka).
    Kinchington PR; Ling P; Pensiero M; Moss B; Ruyechan WT; Hay J
    J Virol; 1990 Sep; 64(9):4540-8. PubMed ID: 2166829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of varicella zoster virus attenuation by evaluation of chimeric parent Oka/vaccine Oka recombinant viruses in skin xenografts in the SCIDhu mouse model.
    Zerboni L; Hinchliffe S; Sommer MH; Ito H; Besser J; Stamatis S; Cheng J; Distefano D; Kraiouchkine N; Shaw A; Arvin AM
    Virology; 2005 Feb; 332(1):337-46. PubMed ID: 15661165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of a current varicella vaccine as a live polyvalent vaccine vector.
    Murakami K; Mori Y
    Vaccine; 2016 Jan; 34(2):296-298. PubMed ID: 25444800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of immunogenic recombinant Oka varicella vaccine expressing hepatitis B virus surface antigen.
    Shiraki K; Hayakawa Y; Mori H; Namazue J; Takamizawa A; Yoshida I; Yamanishi K; Takahashi M
    J Gen Virol; 1991 Jun; 72 ( Pt 6)():1393-9. PubMed ID: 1646279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The immunogenicity of the Oka/Merck varicella vaccine in relation to infectious varicella-zoster virus and relative viral antigen content.
    Bergen RE; Diaz PS; Arvin AM
    J Infect Dis; 1990 Nov; 162(5):1049-54. PubMed ID: 2172393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Vaccines against varicella-zoster virus (VZV)].
    Salleras L; Salleras M; Soldevila N; Prat A; Garrido P; Domínguez Á
    Enferm Infecc Microbiol Clin; 2015; 33(6):411-23. PubMed ID: 26096575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zoster vaccine live (Oka/Merck).
    Robinson DM; Perry CM
    Drugs Aging; 2006; 23(6):525-31; discussion 532-3. PubMed ID: 16872235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.